KROESE, Tiuri E, Richard VAN HILLEGERSBERG, Sebastian SCHOPPMANN, Pieter R A J DESEYNE, Philippe NAFTEUX, Radka OBERMANNOVÁ, Marianne NORDSMARK, Per PFEIFFER, Maria A HAWKINS, Elizabeth SMYTH, Sheraz MARKAR, George B HANNA, Edward CHEONG, Asif CHAUDRY, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Cihan GANI, Christiane J BRUNS, Markus MOEHLER, Theodore LIAKAKOS, John REYNOLDS, Alessio MORGANTI, Riccardo ROSATI, Carlo CASTORO, Domenico UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Paul JEENE, W. VAN SANDICK JOHANNA, Christel MUIJS, Marije SLINGERLAND, Grard NIEUWENHUIJZEN, Bas WIJNHOVEN, Laurens V BEEREPOOT, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Maria ALSINA, Manuel PERA, Tania F KANONNIKOFF, Magnus NILSSON, Matthias GUCKENBERGER, Stefan MONIG, Dorethea WAGNER, Lucjan WYRWICZ, Maaike BERBEE, Ines GOCKEL, Florian LORDICK, Ewen A GRIFFITHS, Marcel VERHEIJ, S. N. VAN ROSSUM PETER and W. M. VAN LAARHOVEN HANNEKE WM. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer. Oxford: Elsevier Science Inc., 2022, vol. 164, March 2022, p. 18-29. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2021.11.032.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
Authors KROESE, Tiuri E, Richard VAN HILLEGERSBERG, Sebastian SCHOPPMANN, Pieter R A J DESEYNE, Philippe NAFTEUX, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Marianne NORDSMARK, Per PFEIFFER, Maria A HAWKINS, Elizabeth SMYTH, Sheraz MARKAR, George B HANNA, Edward CHEONG, Asif CHAUDRY, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Cihan GANI, Christiane J BRUNS, Markus MOEHLER, Theodore LIAKAKOS, John REYNOLDS, Alessio MORGANTI, Riccardo ROSATI, Carlo CASTORO, Domenico UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Paul JEENE, W. VAN SANDICK JOHANNA, Christel MUIJS, Marije SLINGERLAND, Grard NIEUWENHUIJZEN, Bas WIJNHOVEN, Laurens V BEEREPOOT, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Maria ALSINA, Manuel PERA, Tania F KANONNIKOFF, Magnus NILSSON, Matthias GUCKENBERGER, Stefan MONIG, Dorethea WAGNER, Lucjan WYRWICZ, Maaike BERBEE, Ines GOCKEL, Florian LORDICK, Ewen A GRIFFITHS, Marcel VERHEIJ, S. N. VAN ROSSUM PETER and W. M. VAN LAARHOVEN HANNEKE WM (guarantor).
Edition European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.400
RIV identification code RIV/00216224:14110/22:00128454
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.ejca.2021.11.032
UT WoS 000792600200002
Keywords in English Oesophageal neoplasm; Gastric neoplasm; Neoplasm metastasis; Metastasectomy; Radiosurgery; Oligometastasis
Tags 14110811, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2023 15:00.
Abstract
Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n Z 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into up -front local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (< 50%), fair (50%-75%), or consensus (>= 75%). Results: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists.
PrintDisplayed: 20/7/2024 08:23